Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naïve Patients with Bipolar II Disorder

Sheng-Yu Lee, Shiou-Lan Chen, Yun-Hsuan Chang, Po See Chen, San-Yuan Huang, Nian-Sheng Tzeng, Yu-Shan Wang, Liang-Jen Wang, I Hui Lee, Tzu-Yun Wang, Tzung Lieh Yeh, Yen Kuang Yang, Jau-Shyong Hong, Ru-Band Lu, Sheng-Yu Lee, Shiou-Lan Chen, Yun-Hsuan Chang, Po See Chen, San-Yuan Huang, Nian-Sheng Tzeng, Yu-Shan Wang, Liang-Jen Wang, I Hui Lee, Tzu-Yun Wang, Tzung Lieh Yeh, Yen Kuang Yang, Jau-Shyong Hong, Ru-Band Lu

Abstract

Inflammation is thought to be involved in the pathophysiology of bipolar disorder (BP) and metabolic syndrome. Prior studies evaluated the association between metabolic profiles and cytokines only during certain mood states instead of their changes during treatment. We enrolled drug-naïve patients with BP-II and investigated the correlation between changes in mood symptoms and metabolic indices with changes in plasma cytokine levels after 12 weeks of pharmacological treatment. Drug-naïve patients (n = 117) diagnosed with BP-II according to DSM-IV criteria were recruited. Metabolic profiles (cholesterol, triglyceride, HbA1C, fasting serum glucose, body mass index (BMI) and plasma cytokines (TNF-α, CRP, IL-6, and TGF-β) were measured at baseline and 2, 8, and 12 weeks post-treatment. To adjust within-subject dependence over repeated assessments, multiple linear regressions with generalized estimating equation methods were used. Seventy-six (65.0%) patients completed the intervention. Changes in plasma CRP were significantly associated with changes in BMI (P = 1.7E-7) and triglyceride (P = 0.005) levels. Changes in plasma TGF-β1 were significantly associated with changes in BMI (P = 8.2E-6), cholesterol (P = 0.004), and triglyceride (P = 0.006) levels. However, changes in plasma TNF-α and IL-6 were not associated with changes in any of the metabolic indices. Changes in Hamilton Depression Rating Scale scores were significantly associated with changes in IL-6 (P = 0.003) levels; changes in Young Mania Rating Scale scores were significantly associated with changes in CRP (P = 0.006) and TNF-α (P = 0.039) levels. Plasma CRP and TGF-β1 levels were positively correlated with several metabolic indices in BP-II after 12 weeks of pharmacological intervention. We also hypothesize that clinical symptoms are correlated with certain cytokines. These new findings might be important evidence that inflammation is the pathophysiology of clinical symptoms and metabolic disturbance in BP-II.

Trial registration: ClinicalTrials.gov NCT01188148.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Consort flow chart of recruitment.
Figure 1. Consort flow chart of recruitment.

References

    1. Akiskal HS, Pinto O (1999) The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am 22: 517–534, vii.
    1. Angst J, Gamma A, Sellaro R, Lavori PW, Zhang H (2003) Recurrence of bipolar disorders and major depression. A life-long perspective. Eur Arch Psychiatry Clin Neurosci 253: 236–240.
    1. Benazzi F (2001) Bipolar II depression in late life: prevalence and clinical features in 525 depressed outpatients. J Affect Disord 66: 13–18.
    1. Benazzi F, Akiskal HS (2003) Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. J Affect Disord 73: 33–38.
    1. Angst J (2007) The bipolar spectrum. Br J Psychiatry 190: 189–191.
    1. Vieta E, Suppes T (2008) Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord 10: 163–178.
    1. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Maser J, et al. (2003) The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J Affect Disord 73: 19–32.
    1. Pallanti S, Quercioli L, Pazzagli A, Rossi A, Dell'Osso L, et al. (1999) Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder. Am J Psychiatry 156: 1094–1096.
    1. Vieta E, Gastó C, Otero A, Nieto E, Vallejo J (1997) Differential features between bipolar I and bipolar II disorder. Comprehensive Psychiatry 38: 98–101.
    1. Rihmer Z, Pestality P (1999) Bipolar II disorder and suicidal behavior. Psychiatr Clin North Am 22: 667–673, ix–x.
    1. Ghaemi SN, Boiman E, Goodwin FK (2000) Insight and outcome in bipolar, unipolar, and anxiety disorders. Compr Psychiatry 41: 167–171.
    1. MacQueen GM, Young LT (2001) Bipolar II disorder: symptoms, course, and response to treatment. Psychiatr Serv 52: 358–361.
    1. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS (2009) Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 70: 1078–1090.
    1. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R (2007) Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 31: 952–955.
    1. Kim YK, Jung HG, Myint AM, Kim H, Park SH (2007) Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 104: 91–95.
    1. Knijff EM, Breunis MN, Kupka RW, de Wit HJ, Ruwhof C, et al. (2007) An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord 9: 743–753.
    1. O'Brien SM, Scully P, Scott LV, Dinan TG (2006) Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 90: 263–267.
    1. Soderlund J, Olsson SK, Samuelsson M, Walther-Jallow L, Johansson C, et al. (2011) Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. J Psychiatry Neurosci 36: 114–118.
    1. Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN (2004) Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord 82: 309–313.
    1. Knijff EM, Ruwhof C, de Wit HJ, Kupka RW, Vonk R, et al. (2006) Monocyte-derived dendritic cells in bipolar disorder. Biol Psychiatry 59: 317–326.
    1. Brietzke E, Kapczinski F (2008) TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 32: 1355–1361.
    1. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, et al. (2008) Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 23: 87–94.
    1. Ferguson JM, Shingleton RN (2007) An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 30: 136–144.
    1. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, et al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856–864.
    1. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, et al. (2006) A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163: 153–155.
    1. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ (2005) Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 7: 424–430.
    1. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, et al. (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57: 481–489.
    1. Reynolds MF, Sisk EC, Rasgon NL (2007) Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. Curr Med Chem 14: 2799–2812.
    1. Elmslie JL, Porter RJ, Joyce PR, Hunt PJ, Shand BI, et al. (2009) Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust N Z J Psychiatry 43: 53–60.
    1. Chang HH, Yang YK, Gean PW, Huang HC, Chen PS, et al. (2010) The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord 124: 319–323.
    1. Kenna HA, Jiang B, Rasgon NL (2009) Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment. Harv Rev Psychiatry 17: 138–146.
    1. Steen NE, Methlie P, Lorentzen S, Hope S, Barrett EA, et al. (2011) Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability? J Clin Psychiatry 72: 1515–1521.
    1. Taylor V, MacQueen G (2006) Associations between bipolar disorder and metabolic syndrome: A review. J Clin Psychiatry 67: 1034–1041.
    1. Vogelzangs N, Penninx BW (2011) [Depressive symptoms, cortisol, visceral fat and metabolic syndrome]. Tijdschr Psychiatr 53: 613–620.
    1. Karalis KP, Giannogonas P, Kodela E, Koutmani Y, Zoumakis M, et al. (2009) Mechanisms of obesity and related pathology: linking immune responses to metabolic stress. FEBS J 276: 5747–5754.
    1. Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J (2003) Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 11: 525–531.
    1. Das UN (2001) Is obesity an inflammatory condition? Nutrition 17: 953–966.
    1. Bornstein SR, Schuppenies A, Wong ML, Licinio J (2006) Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions. Mol Psychiatry 11: 892–902.
    1. Zhou X, Johnston TP, Johansson D, Parini P, Funa K, et al. (2009) Hypercholesterolemia leads to elevated TGF-beta1 activity and T helper 3-dependent autoimmune responses in atherosclerotic mice. Atherosclerosis 204: 381–387.
    1. Endicott J, Spitzer RL (1978) A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35: 837–844.
    1. Huang SY, Lin WW, Ko HC, Lee JF, Wang TJ, et al. (2004) Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 28: 374–384.
    1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorder-IV-TR. Washington: American Psychiatric Association.
    1. Akiskal HS, Djenderedjian AM, Rosenthal RH, Khani MK (1977) Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am J Psychiatry 134: 1227–1233.
    1. Akiskal HS, Rosenthal RH, Rosenthal TL, Kashgarian M, Khani MK, et al. (1979) Differentiation of primary affective illness from situational, symptomatic, and secondary depressions. Arch Gen Psychiatry 36: 635–643.
    1. Angst J (1998) The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 50: 143–151.
    1. Benazzi F (2001) Is 4 days the minimum duration of hypomania in bipolar II disorder? Eur Arch Psychiatry Clin Neurosci 25: 32–34.
    1. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133: 429–435.
    1. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62.
    1. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278–296.
    1. Zeger SL, Liang KY, Albert PS (1988) Models for longitudinal data: a generalized estimating equation approach. Biometrics 44: 1049–1060.
    1. Shen CW, Chen YH (2012) Model selection for generalized estimating equations accommodating dropout missingness. Biometrics 68: 1046–1054.
    1. Buchner A, Faul F, Erdfelder E (1996) G-power: A Priori, Post Hoc, and Compromise Power Analyses for the Macintosh. Version 2.1.1. ed. Germany.: University of Trier, Trier.
    1. Faul F, Erdfelder E, Buchner A, Lang A (2009) Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41: 1149–1160.
    1. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282: 2131–2135.
    1. Bermudez EA, Ridker PM (2002) C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. Prev Cardiol 5: 42–46.
    1. Marques-Vidal P, Velho S, Waterworth D, Waeber G, von Kanel R, et al. (2012) The association between inflammatory biomarkers and metabolically healthy obesity depends of the definition used. Eur J Clin Nutr 66: 426–435.
    1. Zimmet P, Boyko EJ, Collier GR, de Courten M (1999) Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 892: 25–44.
    1. Vuksan-Cusa B, Sagud M, Jakovljevic M (2010) C-reactive protein and metabolic syndrome in patients with bipolar disorder compared to patients with schizophrenia. Psychiatr Danub 22: 275–277.
    1. Saltevo J, Vanhala M, Kautiainen H, Laakso M (2007) Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with the relative change in body mass index between childhood and adulthood. Diab Vasc Dis Res 4: 328–331.
    1. Grundy SM (1999) Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 83: 25F–29F.
    1. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, et al. (2004) C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47: 1403–1410.
    1. Verma S, Yeh ET (2003) C-reactive protein and atherothrombosis–beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol 285: R1253–1256; discussion R1257–1258.
    1. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82: 4196–4200.
    1. Hsuchou H, Kastin AJ, Mishra PK, Pan W (2012) C-Reactive Protein Increases BBB Permeability: Implications for Obesity and Neuroinflammation. Cell Physiol Biochem 30: 1109–1119.
    1. Zhu CB, Blakely RD, Hewlett WA (2006) The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31: 2121–2131.
    1. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, et al. (2000) Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 49: 1374–1380.
    1. Porreca E, Di Febbo C, Vitacolonna E, Baccante G, Di Castelnuovo A, et al. (2002) Transforming growth factor-beta1 levels in hypertensive patients: association with body mass index and leptin. Am J Hypertens 15: 759–765.
    1. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, et al. (1995) The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med 1: 74–79.
    1. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA (1991) Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest 88: 904–910.
    1. Massague J (1990) The transforming growth factor-beta family. Annu Rev Cell Biol 6: 597–641.
    1. Wang XL, Liu SX, Wilcken DE (1997) Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res 34: 404–410.
    1. Moon YS, Kim DH, Song DK (2004) Serum tumor necrosis factor-alpha levels and components of the metabolic syndrome in obese adolescents. Metabolism 53: 863–867.
    1. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, et al. (2009) Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 116: 214–217.
    1. Pan W, Kastin AJ (1999) Penetration of neurotrophins and cytokines across the blood-brain/blood-spinal cord barrier. Adv Drug Deliv Rev 36: 291–298.
    1. Goldberg JF, Perlis RH, Bowden CL, Thase ME, Miklowitz DJ, et al. (2009) Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry 166: 173–181.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner